These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36191276)

  • 1. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England.
    Guerra-Veloz MF; Han K; Oakes K; Robertson D; Mohamed A; Cannon M; Barnabas A; Shah S; Halford R; Dusheiko G; Agarwal K
    Am J Gastroenterol; 2023 Jun; 118(6):991-1000. PubMed ID: 36191276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic.
    Assoumou SA; Wang J; Nolen S; Eftekhari Yazdi G; Mayer KH; Puro J; Salomon JA; Linas BP
    J Gen Intern Med; 2020 May; 35(5):1477-1483. PubMed ID: 32133577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
    Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
    J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
    Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
    Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shelter-Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness.
    Khalili M; Powell J; Park HH; Bush D; Naugle J; Ricco M; Magee C; Braimoh G; Zevin B; Fokuo JK; Masson CL
    Hepatol Commun; 2022 Jan; 6(1):50-64. PubMed ID: 34628726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
    Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
    Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
    J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C prevalence and cascade of care among patients in the decentralised opioid agonist therapy programme of the canton of St Gallen, Switzerland: a cross-sectional study.
    Wissel K; Vernazza P; Kuster S; Hensel-Koch K; Bregenzer A
    Swiss Med Wkly; 2024 Feb; 154():3352. PubMed ID: 38579293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
    Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
    Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston.
    Beiser ME; Smith K; Ingemi M; Mulligan E; Baggett TP
    Int J Drug Policy; 2019 Oct; 72():129-137. PubMed ID: 30962036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care.
    Valencia J; Lazarus JV; Ceballos FC; Troya J; Cuevas G; Resino S; Torres-Macho J; Ryan P
    Liver Int; 2022 Feb; 42(2):309-319. PubMed ID: 34767680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.
    Mendlowitz AB; Bremner KE; Krahn M; Walker JD; Wong WWL; Sander B; Jones L; Isaranuwatchai W; Feld JJ
    CMAJ; 2023 Apr; 195(14):E499-E512. PubMed ID: 37040993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.
    Seaman A; King CA; Kaser T; Geduldig A; Ronan W; Cook R; Chan B; Levander XA; Priest KC; Korthuis PT
    Int J Drug Policy; 2021 Oct; 96():103359. PubMed ID: 34325969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.
    Byrne CJ; Radley A; Inglis SK; Beer L; Palmer N; Duc Pham M; Allardice K; Wang H; Robinson E; Hermansson M; Semizarov D; Healy B; Doyle JS; Dillon JF
    Aliment Pharmacol Ther; 2022 Jun; 55(12):1512-1523. PubMed ID: 35538396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Cascade of Care Among Perinatal Patients in Maine Diagnosed With Opioid Use Disorder, 2015-2020.
    Pfeiffer M; O'Connor A; Zimmerman C; Thakarar K; Ahrens K
    J Addict Med; 2023 May-Jun 01; 17(3):286-293. PubMed ID: 37267170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis.
    Hashim A; Macken L; Jones A; McGeer M; Aithal G; Verma S
    Int J Drug Policy; 2021 Oct; 96():103342. PubMed ID: 34210551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.